-+ 0.00%
-+ 0.00%
-+ 0.00%

Jade Biosciences Announces 2026 Strategic Plans Including JADE101 Phase 2 Trial Initiation for IgA Nephropathy, Interim Phase 1 Data Release, and Advancement of JADE301 Antibody Program Toward First-in-Human Study

路透·01/05/2026 12:18:32

登錄查看新聞詳情